KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Invested Capital (2016 - 2025)

Biogen has reported Invested Capital over the past 17 years, most recently at $18.3 billion for Q4 2025.

  • Quarterly results put Invested Capital at $18.3 billion for Q4 2025, down 14.14% from a year ago — trailing twelve months through Dec 2025 was $18.3 billion (down 14.14% YoY), and the annual figure for FY2025 was $18.3 billion, down 14.14%.
  • Invested Capital for Q4 2025 was $18.3 billion at Biogen, up from $6.3 billion in the prior quarter.
  • Over the last five years, Invested Capital for BIIB hit a ceiling of $23.9 billion in Q2 2025 and a floor of $6.3 billion in Q3 2025.
  • Median Invested Capital over the past 5 years was $19.9 billion (2022), compared with a mean of $19.2 billion.
  • Biggest five-year swings in Invested Capital: increased 14.71% in 2023 and later tumbled 69.69% in 2025.
  • Biogen's Invested Capital stood at $17.2 billion in 2021, then grew by 14.13% to $19.7 billion in 2022, then rose by 9.75% to $21.6 billion in 2023, then fell by 1.5% to $21.3 billion in 2024, then fell by 14.14% to $18.3 billion in 2025.
  • The last three reported values for Invested Capital were $18.3 billion (Q4 2025), $6.3 billion (Q3 2025), and $23.9 billion (Q2 2025) per Business Quant data.